DING Lieming is the chairman and CEO of Betta Pharmaceuticals Co., Ltd with many other titles: distinguished expert of All-China Federation of Returned Overseas Chinese, Deputy of the 12th National Peoples’ Congress, key member of Chinese National Key Special Program of Innovative Drugs, and Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA).

Ding Lieming came back to China at the middle of 2002 to start up Betta Pharmaceuticals Co.,Ltd, a company focusing on research and development of new drugs. In August 2011, Betta Pharmaceutical launched Icotinib (Conmana), the first home-made drug in China for targeted therapy of non-small cell lung cancer, which is the milestone for Chinese anticancer industry. In 2012 and 2014, the WIPO and SIPO of China issued Gold award to Icotinib for its two invention patents. Icotinib won the first prize of the National Science and Technology Progress Award in 2016, which is the first time that the chemical and pharmaceutical industry won the prize. In the same year, icotinib also won the China Industry Award, the top accolade of industry sector. To date, icotinib has the total sales revenue of over 4.0 billion RMB and has benefited nearly 140,000 patients.